Osomes and exosoms) by Izon S1PR4 web system, revealed the presence of vesicles in typical size about 200 nm. The vesicular morphology was confirmed by atomic force microscopy, whilst the protein markers had been assessed accordingly to ISEV suggestions by western blotting. High-sensitivity flow cytometry (Apogee Flow technique) confirmed the presence of numerous MSCspecific markers on MSC-EVs such as receptors and adhesions. We also found MSC-EVs to be enriched in mRNAs, miRNAs and severalThursday May possibly 18,1 CIC bioGUNE; 2Universidad Complutense Madrid, Madrid, Spain; 3CIC bioGUNE-Liverpool University, Liverpool, United Kingdomproteins from donor MSC cells as shown by real-time RT-PCR and mass spectroscopy, respectively. We identified MSC-MVs to carry many transcripts regulating SC cardiac and angiogenic differentiation capacity. Importantly, our data (i) indicated an excellent impact of MSC-EVs on proangiogenic capacity of heart endothelial cells in vitro also as (ii) confirmed their regenerative possible in vivo by displaying enhanced heart histology, anatomy and function in murine AMI model. The increase in variety of new capillaries inside the spot of EV injection, might suggest the elevated perfusion as one of the big mechanisms involved inside the MSC-EV regeneration capacity in vivo. In summary, our information demonstrated that MSC-derived EVs represent all-natural nanocarriers transferring bioactive content to mature target cells and playing an effective function in heart regeneration in vivo. We conclude that MSC-EVs may represent novel safe therapeutic tool in heart tissue regeneration, option or supporting to entire cell-based therapy in heart repair.PT03.Biodistribution and efficacy of extracellular vesicles from cardiosphere-derived cells Jennifer L. Johnson1, Ahmed Ibrahim1, Chris Sakoda1, Kenny Gouin2, Kiel Peck1, Liang Li1, Travis Antes3, Houman Hemmati1, Rachel Smith1, Linda Marban1 and Luis Rodriguez-BorladoCapricor Therapeutics; 2Cedars Sinai, CA, USA; 3Cedars-Sinai Medical Centre, Heart Institute, CA, USAIntroduction: Extracellular vesicles created by cardiosphere-derived cells (CDC-EVs) have already been shown to recapitulate the therapeutic Atg4 MedChemExpress activity of parent cells in heart-related ailments. The capability of CDC-EVs to lessen inflammation, attenuate fibrosis, and activate regeneration make them incredibly appealing for inflammatory ailments treatment. Capricor is evaluating the usage of CDC-EVs for the treatment of ocular graft versus host illness (oGVHD), an indication where the item may be locally delivered. No earlier studies have already been published analysing EVs biodistribution right after eye delivery. Right here, we show in vivo biodistribution of CDC-EVs in an ocular alkali burn mouse model immediately after subconjunctival or topical delivery, employing a novel qPCR-based process. We also analysed the therapeutic potential of CDC-EVs in mouse and rabbit models. Lastly, CDC-EVs uptake by diverse cellular sorts was analysed in vitro to recognize CDC-EVs target cells. Techniques: Unmodified human CDC-EVs were injected in to the subconjunctival space or administered topically to healthier or injured mouse eyes. In vitro uptake of dye-labelled EVs was measured by detecting intracellular fluorescence in treated cells by flow cytometry. In vivo biodistribution tracking was then performed making use of a sensitive qPCR strategy tracking a YRNA fragment abundant in CDC-EVs. Therapeutic activity of CDC-EVs was evaluated within a rat model of corneal alkali burn injury and a rabbit model of Sjgren’s syndrome. Outcome.